

# Maria Ilaria Del Principe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4290780/publications.pdf>

Version: 2024-02-01

62  
papers

3,078  
citations

186209

28  
h-index

161767

54  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016 survey. <i>Mycoses</i> , 2022, 65, 171-177.	1.8	3
2	Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. <i>Haematologica</i> , 2022, 107, 996-999.	1.7	15
3	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
4	Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1754-1757.	0.6	2
5	In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1776.	1.0	1
6	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.0	1
7	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52.	0.8	10
8	ESCCA/ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow cytometry in hematological malignancies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 269-281.	0.7	13
9	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
10	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6246.	1.7	9
11	Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. <i>Haematologica</i> , 2020, 106, 39-45.	1.7	14
12	Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. <i>American Journal of Hematology</i> , 2020, 95, 1466-1472.	2.0	42
13	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM study). <i>Mycoses</i> , 2020, 63, 1094-1100.	1.8	6
14	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097.	2.0	25
15	Applications and efficiency of flow cytometry for leukemia diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1089-1097.	1.5	14
16	An evaluation of enasidenib for the treatment of acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1935-1942.	0.9	5
17	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	1.3	11
18	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	1.8	39

#	ARTICLE	IF	CITATIONS
19	Longitudinal detection of <i>DNMT3A</i> <sup>R882H</sup> transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	2.0	7
20	Thrombosis in adult patients with acute leukemia. <i>Current Opinion in Oncology</i> , 2017, 29, 448-454.	1.1	38
21	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	2.8	98
22	A cluster of <i>Geotrichum clavatum</i> ( <i>Saprochaete clavata</i> ) infection in haematological patients: a first Italian report and review of literature. <i>Mycoses</i> , 2016, 59, 594-601.	1.8	44
23	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85.	1.7	53
24	Extensive toxic epidermal necrolysis following brentuximab vedotin administration. <i>Annals of Hematology</i> , 2015, 94, 355-356.	0.8	9
25	Minimal residual disease as biomarker for optimal biologic dosing of <i>ARA-C</i> in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131.	2.0	12
26	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014075.	0.5	50
27	Advances in the treatment of elderly and frail patients with acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2014, 26, 663-669.	1.1	4
28	Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. <i>Annals of Hematology</i> , 2014, 93, 1611-1612.	0.8	0
29	High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1509-1513.	0.8	30
30	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	0.8	34
31	Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. <i>Thrombosis Research</i> , 2013, 132, 511-514.	0.8	41
32	Clinical significance of <i>7545 delCT</i> <i>NOTCH1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	1.2	14
33	Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, e189-e191.	0.8	7
34	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-341.	0.6	246
35	A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631.	2.0	32
36	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	0.6	126

#	ARTICLE	IF	CITATIONS
37	The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 383-387.	1.2	15
38	Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	3.2	44
39	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106.	0.6	16
40	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	1.8	19
41	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	1.2	106
42	Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 857-858.	0.6	2
43	Monitoring of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 582-588.	1.1	24
44	Evaluation of the prognostic relevance of sLe <sup>x</sup> and ICAM1 expression in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2008, 80, 107-114.	1.1	7
45	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	2.0	86
46	Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951.	0.8	165
47	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	0.6	226
48	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. <i>Haematologica</i> , 2007, 92, 605-611.	1.7	76
49	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	0.6	62
50	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	0.6	171
51	Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2006, 85, 136-138.	0.8	5
52	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	0.7	38
53	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363.	2.0	49
54	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1787-1800.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	2.0	30
56	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752.	2.0	45
57	Apoptosis and immaturity in acute myeloid leukemia. <i>Hematology</i> , 2005, 10, 25-34.	0.7	19
58	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	1.2	26
59	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 121, 730-738.	1.2	32
60	Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 445-450.	0.6	11
61	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131.	0.6	309
62	Clinical significance of CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2001, 98, 2633-2639.	0.6	242